Does the 2026 BPC-157 Hamstring Strain RCT (NCT07437547) Use MRI Injury Volume and Return-to-Sport as Co-Primary Endpoints?

Yes. NCT07437547, a Phase 2 randomised, double-blind, placebo-controlled trial currently recruiting in 2026, designates two co-primary endpoints: time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14. The trial enrols 120 adults with MRI-confirmed acute grade II hamstring strain and administers subcutaneous BPC-157 or placebo once daily for 14 days alongside a standardised rehabilitation programme.

What Is the Full Design of NCT07437547 and Why Were These Endpoints Chosen?

NCT07437547 (BPC-HAMSTR) is a Phase 2, parallel-group, double-blind, placebo-controlled trial sponsored by Hudson Biotech at Peking University Shenzhen Hospital. It targets 120 participants aged 18–45 with MRI-confirmed acute grade II hamstring strain, onset within 72 hours of screening. Co-primary endpoints capture both functional recovery time and structural MRI injury volume change at Day 14.

Functional recovery time is the outcome most relevant to athletes and clinicians, but it is susceptible to subjective reporting bias and variable rehabilitation intensity. MRI-assessed injury volume at Day 14 provides an objective, blinded structural correlate independent of patient-reported pain tolerance. Pairing these endpoints as co-primaries requires the trial to demonstrate benefit on both dimensions before a positive conclusion can be drawn, raising the evidentiary bar above single-endpoint designs.

Participants in both arms receive a standardised rehabilitation protocol to control for physiotherapy variability, which has historically confounded musculoskeletal recovery trials. The active arm receives subcutaneous BPC-157 once daily for 14 days; the control arm receives a matched placebo injection on the same schedule. Blinding is maintained at the participant, investigator, and outcome assessor levels.

Completion is expected in February 2027, making NCT07437547 the first adequately powered, prospective, controlled human trial to generate efficacy data on BPC-157 for any musculoskeletal indication. Its results will be directly relevant to the ongoing FDA regulatory discussion about BPC-157's status as a compounded bulk substance.

What Preclinical Evidence Provides the Mechanistic Rationale for Testing BPC-157 in Muscle Injury?

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective sequence in human gastric juice. In rodent injury models, it accelerates structural repair through three converging pathways: VEGF-driven angiogenesis, enhanced growth hormone receptor expression in fibroblasts, and increased collagen synthesis at the injury site. All supporting data remain at preclinical level.

A 2025 narrative review by McGuire et al. (PMC12446177) found that BPC-157 accelerates tendon and ligament repair primarily through enhanced fibroblast proliferation and collagen synthesis, with focal adhesion kinase signalling identified as a central mediator. A parallel systematic review by Vasireddi et al. (PMC12313605), classified as level IV–V evidence, concluded that BPC-157 shows promise for musculoskeletal injury recovery but that all supporting data derive from animal models or uncontrolled human observations.

The VEGF-angiogenesis pathway is particularly relevant to hamstring strain pathophysiology. Grade II strains involve partial disruption of muscle fibre architecture with associated haematoma formation and localised ischaemia. Accelerating neovascularisation theoretically shortens the inflammatory phase and supports earlier myofibre regeneration.

Brcic et al. demonstrated VEGF upregulation by BPC-157 in both crushed and transected muscle models in rats, providing a mechanistic link to the MRI-volume endpoint used in NCT07437547. Growth hormone receptor upregulation in tendon fibroblasts, documented in in vitro studies, offers a second pathway through which BPC-157 may promote extracellular matrix remodelling. However, extrapolating fibroblast culture data to in vivo human muscle repair requires caution: the cellular environment and paracrine signalling context differ substantially from a healing hamstring in an ambulatory patient.

How Will MRI Injury Volume Be Measured and What Are the Methodological Considerations?

MRI injury volume in muscle strain trials is quantified using T2-weighted or STIR sequences to delineate oedema and haemorrhage within the injured muscle belly. The Day 14 timepoint in NCT07437547 captures the transition from acute inflammatory oedema to early reparative remodelling — a window in which a biologically active intervention would be expected to produce a measurable volumetric difference.

Intra- and inter-rater reliability of MRI muscle strain volumetry is a recognised methodological challenge, with intraclass correlation coefficients ranging from 0.85 to 0.97 in elite-athlete studies when experienced radiologists perform segmentation. NCT07437547 does not publicly specify whether centralised blinded reading will be employed, a design detail that will materially affect the credibility of the MRI endpoint.

Reduced oedema volume at two weeks does not necessarily predict faster return to sport if the underlying myofibre architecture remains disrupted. The trial's co-primary design addresses this partially by requiring concurrent improvement in functional recovery time. However, the mechanistic link between the two endpoints has not been validated in any prior controlled human BPC-157 study.

How Is Return to Unrestricted Sport Defined and What Criteria Will Govern Clearance?

Return to unrestricted sport (RTS) typically integrates pain-free full-range hip flexion and knee extension, normalised hamstring strength on isokinetic testing, and sport-specific movement competency. The specific RTS criteria in NCT07437547 have not been published in advance, but the standardised rehabilitation protocol across both arms implies that clearance will follow a pre-specified algorithm rather than clinician discretion alone.

Hamstring re-injury rates after premature RTS clearance are well-documented in the sports medicine literature, ranging from 12% to 34% in professional football cohorts within the first season after index injury. Any intervention that accelerates RTS without proportionally reducing re-injury risk would represent a net harm rather than a benefit. The trial protocol does not appear to include re-injury rate as a secondary endpoint, which is a notable gap given this clinical context.

The 72-hour enrolment window — requiring injury onset within three days of screening — ensures that participants enter the trial during the acute inflammatory phase, before spontaneous resolution substantially reduces the measurable effect size. This design choice is methodologically sound but may limit generalisability to athletes who present for evaluation later in the injury course, as commonly occurs in recreational sport settings.

What Is BPC-157's Current Regulatory Status and How Does This Trial Address the Evidentiary Gap?

BPC-157 holds no FDA approval and carries no active approved IND in the United States as of mid-2026. The FDA's Pharmacy Compounding Advisory Committee voted in July 2026 against adding BPC-157 to the 503A bulk list, citing absent human trial data. NCT07437547 is the first Phase 2 controlled human trial for a musculoskeletal indication and directly addresses that evidentiary gap.

The FDA's interim classification of BPC-157 as a Category 2 bulk substance — indicating potential safety risks and limited safety data — reflects concerns about immunogenicity with parenteral administration and the absence of human pharmacokinetic characterisation. NCT07437547 will generate the first controlled human safety dataset for subcutaneous BPC-157 at a defined dose and duration. These data are prerequisite for any future IND or 503A nomination regardless of the efficacy outcome.

NCT07437547 is registered under Hudson Biotech as sponsor and is conducted at Peking University Shenzhen Hospital outside the United States. Results generated under a foreign regulatory framework may require additional bridging studies or a US-specific IND filing before they can support a domestic regulatory submission. The trial's February 2027 completion date means peer-reviewed results are unlikely before late 2027 at the earliest.

What Safety Parameters Are Being Monitored and What Theoretical Risks Apply?

The trial monitors standard Phase 2 safety parameters: treatment-emergent adverse events, serious adverse events, injection-site reactions, and laboratory safety markers at baseline and Day 14. Theoretical risks include immunogenic reactions to a non-endogenous peptide administered parenterally, potential off-target effects via growth hormone receptor modulation, and unknown interactions with concurrent NSAID use common in acute musculoskeletal injury.

No serious adverse events have been reported in the preclinical BPC-157 literature across multiple rodent species and administration routes, including subcutaneous, intramuscular, intraperitoneal, and oral delivery. However, the absence of a toxicity signal in animal models does not exclude immunogenic or idiosyncratic reactions in humans, particularly with repeated parenteral dosing of a synthetic peptide not present in the human proteome at physiological concentrations.

The 14-day treatment duration limits the safety observation window to the acute injury phase. Long-term safety data — relevant if BPC-157 were to be used in chronic or recurrent injury management — will not be generated by this trial. Practitioners reviewing the eventual results should interpret the safety findings within this constrained temporal scope.

How Should Clinicians Interpret the Trial Results When They Become Available?

A positive result on both co-primary endpoints would be the first controlled human evidence that BPC-157 accelerates structural and functional recovery from musculoskeletal injury. It would not constitute sufficient evidence for clinical adoption: a single Phase 2 trial at one centre, in one injury type, within a defined age range, does not establish generalisability across populations or injury grades.

A null result — failure to demonstrate benefit on one or both co-primary endpoints — would not definitively refute the preclinical mechanistic evidence. Null results in Phase 2 trials frequently reflect inadequate dose selection, suboptimal intervention timing, or endpoint insensitivity rather than true absence of biological activity. The trial's design choices — 14-day treatment, Day 14 MRI assessment, subcutaneous route — should be evaluated critically in the context of any null finding.

Clinicians should also attend to the secondary endpoints, which are expected to include pain scores, functional movement assessments, and patient-reported outcome measures. Discordance between primary and secondary endpoints — for example, MRI volume reduction without functional improvement — would carry important mechanistic implications about the relationship between structural healing and clinical recovery in hamstring strain.

Until results are published in a peer-reviewed journal with full protocol and statistical analysis plan disclosure, BPC-157 remains an investigational compound with no established clinical role in hamstring strain management. Framing the trial as confirmatory of efficacy before data are available misrepresents the purpose of a Phase 2 study, which is to generate — not confirm — evidence.

Safety and Regulatory Note

BPC-157 is not approved by the FDA or any major regulatory authority and is classified as investigational. Outside a registered clinical trial, parenteral administration occurs without regulatory safety oversight. The FDA has identified immunogenicity concerns and has not cleared any US IND for BPC-157. Nothing here should be interpreted as support for off-label or compounded use. What New Human Safety Data Exist for BPC-157 in Musculoskeletal Recovery and Gut Repair in 2026? What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears? Does BPC-157 Improve Tendon Healing and Ligament Repair in Human Orthopaedic Surgical Populations in 2026?